Document is current
Any future updates will be listed below
-
Authors
Velardi, Enrico https://orcid.org/0000-0001-8383-0453
Clave, Emmanuel https://orcid.org/0000-0001-8217-5039
Arruda, Lucas C. M. https://orcid.org/0000-0002-8573-9618
Benini, Francesca https://orcid.org/0000-0003-2900-6636
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
Toubert, Antoine https://orcid.org/0000-0002-7308-7317
-
Funding
Funding for this research was provided by:
Amy Strelzer Manasevit Research Program
Italian Association for Cancer Research (My First Grant AIRC)
Italian Association for Cancer Research (Special Program Metastatic disease: the key unmet need in oncology 5 per mille 2018 Project Code 21147 and Accelerator Award 2017 INCAR)
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN ID 2017 WC8499_004)
Ministero della Salute (RF-2016-02364388)
French Government’s Investissement d’Avenir Program
Laboratoire d’Excellence “Milieu Intérieur” Grant (ANR-10-LABX-69-01)
Laboratoire d’Excellence “Milieu Intérieur” Grant (ANR-10-LABX-69-01)
Agence Nationale de la Recherche (Project RANKLthym ANR-19- CE18-0021-02)
Agence Nationale de la Recherche (Project RANKLthym ANR-19- CE18-0021-02)
Italian Ministry of Health
- License Information
-
More Information
Article History
Received: 15 September 2020
Accepted: 14 November 2020
First Online: 8 January 2021
Compliance with ethical standards
:
: E.V. has acted as a consultant and received honorarium from Ferring Pharmaceuticals. Two provisional patent applications have been filed (US 15/033,178 and US 62/566,897) with E.V. listed as inventor. F.L. participated in advisory boards or speakers bureaus for Amgen, Novartis, Bellicum Pharmaceutical, Miltenyi, Medac, Neovii, Jazz Pharmaceutical and Takeda. A.T., F.B., and E.C. have no conflict of interest.
